Full Text
PND16 Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Primary Progressive Multiple Sclerosis

Abstract

Authors

Maio D Di J. Wu A. Stavropoulos Alvarez J Sanchez D. Diles

Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×